ArticleInternational journal of nanomedicine2025
Nano-Emulsion Incorporating Squalene and Mn
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms and Applications of Manganese-Based Materials in Tumor Immunotherapy.Molecules (Basel, Switzerland) · 2026Review
- Tea saponin-soybean oil submicron emulsion promotes durable protective immunity againstFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective protection against infections requires humoral and cellular immune responses. Although current subunit vaccines primarily induce antibodies, they often fail to elicit strong CD8 Methods: The ultrasonic emulsification was used to prepared nano-emulsion system (Sq@TA/Mn) combining Sq and Mn Results: The Sq@TA/Mn nano-emulsion was constructed through ultrasonic emulsification. The nano-emulsion efficiently adsorbed OVA to form a Sq@TA/Mn@OVA vaccine. The OVA vaccine exhibited a favorable safety profile, enhanced ROS generation, dendritic cell uptake, and improved antigen retention at the injection site. Compared to Alum, this vaccine enhanced the production of OVA-specific antibodies and IFN-γ, promoted the expansion of spleen effector memory T cells, and increased the population of lung-resident memory T cells.The Sq@TA/Mn adjuvant elicited higher rPal-specific IgG, IgG1, and IgG2a titers and improved the protective efficacy against infection as compared with Alum. Conclusion: This study provides a novel method for the co-delivery of Mn
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.